View in EDS

Impact of CD44 alternative splicing on the response to anticancer drugs.

Saved in:
Bibliographic Details
Title: Impact of CD44 alternative splicing on the response to anticancer drugs.
Authors: Marin JJG; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain. Electronic address: jjgmarin@usal.es., Asensio M; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain. Electronic address: masensio002@usal.es., Álvarez-Fernández L; Departamento de Ciencias Biomédicas, Instituto de Desarrollo Ganadero y Sanidad Animal (INDEGSAL), Universidad de León, León, Spain. Electronic address: lalvf@unileon.es., Hortelano-Hernandez N; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain. Electronic address: NazaretHortelano@usal.es., Delgado-Calvo K; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain. Electronic address: kevindc@usal.es., Marijuan RP; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain. Electronic address: rebeca.penmar@usal.es., Perez-Silva L; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain. Electronic address: laurapsilva@usal.es., Benizri LO; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Department of Biotechnology, University of Mannheim, Mannheim, Germany. Electronic address: lauraonesta3005@gmail.com., Gallai D; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Department of Biology, University of Florence, Florence, Italy. Electronic address: gallaidaniele@gmail.com., Lozano E; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain. Electronic address: elisa_biologia@usal.es., Macias RIR; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain. Electronic address: rociorm@usal.es., Briz O; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain. Electronic address: obriz@usal.es., Reviejo M; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain. Electronic address: maredi@usal.es.
Source: Biochemical pharmacology [Biochem Pharmacol] 2026 May 30; Vol. 251 (Pt 1), pp. 118111. Date of Electronic Publication: 2026 May 30.
Publication Type: Journal Article; Review
Journal Info: Publisher: Elsevier Science Country of Publication: England NLM ID: 0101032 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2968 (Electronic) Linking ISSN: 00062952 NLM ISO Abbreviation: Biochem Pharmacol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42218981
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Impact of CD44 alternative splicing on the response to anticancer drugs.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Marin+JJG%22">Marin JJG</searchLink>; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain. Electronic address: jjgmarin@usal.es.<br /><searchLink fieldCode="AU" term="%22Asensio+M%22">Asensio M</searchLink>; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain. Electronic address: masensio002@usal.es.<br /><searchLink fieldCode="AU" term="%22Álvarez-Fernández+L%22">Álvarez-Fernández L</searchLink>; Departamento de Ciencias Biomédicas, Instituto de Desarrollo Ganadero y Sanidad Animal (INDEGSAL), Universidad de León, León, Spain. Electronic address: lalvf@unileon.es.<br /><searchLink fieldCode="AU" term="%22Hortelano-Hernandez+N%22">Hortelano-Hernandez N</searchLink>; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain. Electronic address: NazaretHortelano@usal.es.<br /><searchLink fieldCode="AU" term="%22Delgado-Calvo+K%22">Delgado-Calvo K</searchLink>; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain. Electronic address: kevindc@usal.es.<br /><searchLink fieldCode="AU" term="%22Marijuan+RP%22">Marijuan RP</searchLink>; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain. Electronic address: rebeca.penmar@usal.es.<br /><searchLink fieldCode="AU" term="%22Perez-Silva+L%22">Perez-Silva L</searchLink>; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain. Electronic address: laurapsilva@usal.es.<br /><searchLink fieldCode="AU" term="%22Benizri+LO%22">Benizri LO</searchLink>; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Department of Biotechnology, University of Mannheim, Mannheim, Germany. Electronic address: lauraonesta3005@gmail.com.<br /><searchLink fieldCode="AU" term="%22Gallai+D%22">Gallai D</searchLink>; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Department of Biology, University of Florence, Florence, Italy. Electronic address: gallaidaniele@gmail.com.<br /><searchLink fieldCode="AU" term="%22Lozano+E%22">Lozano E</searchLink>; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain. Electronic address: elisa_biologia@usal.es.<br /><searchLink fieldCode="AU" term="%22Macias+RIR%22">Macias RIR</searchLink>; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain. Electronic address: rociorm@usal.es.<br /><searchLink fieldCode="AU" term="%22Briz+O%22">Briz O</searchLink>; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain. Electronic address: obriz@usal.es.<br /><searchLink fieldCode="AU" term="%22Reviejo+M%22">Reviejo M</searchLink>; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain. Electronic address: maredi@usal.es.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220101032%22">Biochemical pharmacology</searchLink> [Biochem Pharmacol] 2026 May 30; Vol. 251 (Pt 1), pp. 118111. <i>Date of Electronic Publication: </i>2026 May 30.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Review
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science%22">Elsevier Science </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>0101032 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1873-2968 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200062952%22">00062952 </searchLink><i>NLM ISO Abbreviation: </i>Biochem Pharmacol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42218981
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.bcp.2026.118111
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 118111
    Titles:
      – TitleFull: Impact of CD44 alternative splicing on the response to anticancer drugs.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Marin JJG
      – PersonEntity:
          Name:
            NameFull: Asensio M
      – PersonEntity:
          Name:
            NameFull: Álvarez-Fernández L
      – PersonEntity:
          Name:
            NameFull: Hortelano-Hernandez N
      – PersonEntity:
          Name:
            NameFull: Delgado-Calvo K
      – PersonEntity:
          Name:
            NameFull: Marijuan RP
      – PersonEntity:
          Name:
            NameFull: Perez-Silva L
      – PersonEntity:
          Name:
            NameFull: Benizri LO
      – PersonEntity:
          Name:
            NameFull: Gallai D
      – PersonEntity:
          Name:
            NameFull: Lozano E
      – PersonEntity:
          Name:
            NameFull: Macias RIR
      – PersonEntity:
          Name:
            NameFull: Briz O
      – PersonEntity:
          Name:
            NameFull: Reviejo M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 30
              M: 05
              Text: 2026 May 30
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1873-2968
          Numbering:
            – Type: volume
              Value: 251
            – Type: issue
              Value: Pt 1
          Titles:
            – TitleFull: Biochemical pharmacology
              Type: main
ResultId 1